Park and Sonpavde on Nivolumab Plus Gemcitabine/Cisplatin in Cisplatin-Eligible Urothelial Cancer

Drs Park and Sonpavde discuss the CheckMate901 trial, which showed survival improvements with nivolumab plus chemotherapy in metastatic urothelial cancer.

In Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a genitourinary (GU) medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, discusses trial and treatment updates for patients with inoperable or metastatic urothelial cancer.

In part 2 of this 3-part series, Dr Park converses with Guru Sonpavde, MD, about updated data from part 1 of the phase 3 CheckMate901 trial (NCT03036098), which assessed gemcitabine plus cisplatin alone vs gemcitabine plus cisplatin and nivolumab (Opdivo) in cisplatin-eligible patients with untreated inoperable or metastatic urothelial cancer. Dr Sonpavde is the medical director of GU Oncology, the assistant director of the Clinical Research Unit, and the Christopher K. Glanz Chair for Bladder Cancer Research at AdventHealth Cancer Institute in Orlando, Florida.

Drs Park and Sonpavde discuss results from this trial, which showed significant improvements in overall survival and progression-free survival with the addition of nivolumab.

Related Content